Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
Open Access
- 30 October 2018
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 16 (4) , 609-618
Abstract
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians' global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation. A total of 429 IBD (378 ulcerative colitis, 51 Crohn's disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78-3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81-3.11; P=0.172]). Based on the physicians' global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months' observation period. The overall eradication rate was 84.0%-comparable to previous reports in non-IBD patients. H. pylori eradication therapy does not alter the short-term disease activity of IBD.Keywords
This publication has 34 references indexed in Scilit:
- Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s diseaseBMC Gastroenterology, 2017
- Pathogenic role of the gut microbiota in gastrointestinal diseasesIntestinal Research, 2016
- Opportunistic Infections Due to Inflammatory Bowel Disease TherapyInflammatory Bowel Diseases, 2014
- Role of commensal gut bacteria in inflammatory bowel diseasesGut Microbes, 2012
- Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of GastroenterologyCanadian Journal of Gastroenterology and Hepatology, 2005
- Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategiesAlimentary Pharmacology & Therapeutics, 2003
- Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugsThe Lancet, 1998
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988